Trial reportWorld journal of surgical oncology2026
Immune-inflammatory-fibrinogen score as a novel prognostic biomarker in patients with gastric cancer undergoing radical gastrectomy: a multicenter study.
Trial report in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02327481 (Randomized Controlled Trials Comparing Clinical Outcomes of 3D Versus 2D Laparoscopic Surgery for Gastric Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Controlled Trials Comparing Clinical Outcomes of 3D Versus 2D Laparoscopic Surgery for Gastric Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundGastric cancer (GC) progression involves changes in immune responses, inflammation, and coagulation. The prognostic value of related biomarkers remains unclear. This study aimed to develop a novel immune-inflammation-fibrinogen score (FSL score) to predict outcomes in GC patients after radical gastrectomy.
methodsClinicopathological data from 401 GC patients enrolled in a randomized controlled trial (2015-2016; ClinicalTrials.gov: NCT02327481) were retrospectively analyzed as the training cohort, with 173 patients included for external validation. Cox regression was used to construct the FSL score based on preoperative hematological markers and to evaluate its association with overall survival (OS) and recurrence-free survival (RFS). A nomogram incorporating the FSL score and clinicopathological factors was developed and evaluated using the C-index, time-dependent AUC, calibration curves, AIC, BIC, and decision curve analysis (DCA), and compared with the AJCC 8th TNM staging system.
resultsPatients with high FSL scores had significantly better 3-year OS (training cohort: 87.4% vs. 71.3%, p = 0.001; validation cohort: 68.4% vs. 42.6%, p = 0.009) and RFS (training cohort: 81.0% vs. 67.6%, p = 0.001; validation cohort: 72.4% vs. 54.9%, p = 0.025). The FSL score independently predicted OS and RFS (all p < 0.05). A nomogram integrating the FSL score, preoperative CEA level, pT stage, pN stage, and postoperative chemotherapy outperformed the TNM system for OS (C-index: 0.806 vs. 0.757; AIC: 1378.25 vs. 1395.73; BIC: 1390.49 vs. 1394.10) and RFS (C-index: 0.803 vs. 0.763; AIC: 1310.10 vs. 1319.08; BIC: 1320.11 vs. 1322.26), with good discrimination, calibration, and clinical utility confirmed by DCA and external validation.
conclusionsThe FSL score is a promising prognostic biomarker for GC patients undergoing radical gastrectomy. The proposed nomogram enables accurate and individualized survival prediction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.